[Abstract]177Lu-labeled prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) is an innovative treatment approach that precisely delivers β radiation emitted by177Lu to prostate cancer cells, causing radiation ...
[Abstract]177Lu-labeled prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) is an innovative treatment approach that precisely delivers β radiation emitted by 177Lu to prostate cancer cells, causing radiation damage to the tumor cells’ DNA and thereby eliminating the tumor. At ...
泸州市-西南医科大学核素精准诊疗研究项目(2016lzxnyd-g01) 详细信息 progress in radioligand therapy with 177 lu-psma for the treatment of metastatic castration-resistant prostate cancer yanhong zhao , yue chen , department of nuclear medicine, affiliated hospital of southwest medical university, nuclear ...
2. Hansen AR, Probst S, Tutrone RF, et al. 1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration-resistant prostate cancer (mCRPC): initial results from SPLASH. Ann Oncol. 2022;33(suppl 7):S1185. doi:10.1016/j.annonc.2022.07...
is a cell surface membrane protein highly expressed on prostate cancer cells. 1 , 2 lutetium lu 177 vipivotide tetraxetan (lu-177) psma was approved by the us food and drug administration march 23, 2022, for the treatment of psma-positive, metastatic castration-resistant prostate cancer (...
3. Study evaluating mCRPC treatment using PSMA [Lu-177]-PNT2002 therapy after second-line hormonal treatment (SPLASH). ClinicalTrials.gov. Updated November 2, 2023. Accessed December 19, 2023.
Prostate-specific membrane antigen (PSMA) is expressed in high-risk prostate cancer (PCa). PSMA has potential as a basis for new diagnostics and theragnostics. 177Lu-PSMA radioligand therapy is...doi:10.1007/s40336-018-0274-yKairemo, Kalevi...
参考来源:Novartis Pharma AG;Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer;March 23, 2022 16:19 ET 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。
来自 ResearchGate 喜欢 0 阅读量: 30 作者: W Devlies,OVD Gaer,AVD Maele 展开 摘要: Aim In this study, we want to compare the efficacy and toxicity of 177 Lu-J591 PSMA antibody with the 177 Lu-DKFZ-617 PSMA ligand. 展开 DOI: 10.13140/RG.2.2.35588.73601 年份: 2016 ...
[2] Heidegger I, Kesch C, Kretschmer A, et al. Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer-a state of the art review[J]. Therapeutic Advances in Medical Oncology, 2022, 14: 17588359221081922. ...